twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2003
vol. 105
 
Share:
Share:
abstract:
Original paper

Correction of high myopia with anterior chamber angle-supported phakic intraocular lenses – own results

Stanisława Gierek-Ciaciura
1
,
Krzysztof Ochalik
1
,
Ariadna Gierek-Łapińska
1
,
Barbara Myga
1

  1. Z Samodzielnego Publicznego Szpitala Klinicznego nr 5 Śląskiej Akademii Medycznej w Katowicach
Online publish date: 2003/12/21
View full text Get citation
 
Introduction
To evaluate the early results: predictability, efficacy and safety of implanting new model of anterior chamber IOL for high myopia.

Material and methods
ICARE myopia lens (Corneal) was implanted in 20 eyes of 12 patients with preoperative myopia that ranged from -10D to -23,5D. Mean patient age was 32,3 years. The follow-up period was 6 months. The desired outcome was emmetropia.

Results
Eighteen eyes (85%) had a postoperative refraction at the last follow-up examination in a range ±1,0 D of emmetropia. The postoperative refraction remained stable during the entire follow-up period. Mean visual acuity before surgery, corrected with spectacle improved from 0,5 to 0,68 postoperatively without glasses in 3 months time. There was no loss in visual acuity after operation. We didn't encounter major complications. Mean endothelial cell density reduction was 3,2% in our 3 months study.

Conclusions
Implantation of ICARE myopia lens to correct high myopia resulted in a stable and predictable refractive outcome. Further investigation is necessary to evaluate long-term stability and safety of this procedure.

keywords:

high myopia, anterior chamber phakic intraocular lenses

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.